{
    "ASSERTIONS": {
        "id": 760,
        "context": null,
        "description": "Signature 10 is related to mutant pole, which may suggest sensitivity to immunotherapy. ",
        "disease": {
            "name": null,
            "oncotree_code": null,
            "oncotree_term": null
        },
        "therapy_name": "Pembrolizumab",
        "therapy_type": "Immunotherapy",
        "clinical_significance": "sensitivity",
        "predictive_implication": "Inferential",
        "favorable_prognosis": null,
        "created_on": "03/31/21",
        "last_updated": "2019-02-04",
        "submitted_by": "breardon@broadinstitute.org",
        "validated": true,
        "source_ids": 150,
        "variant": {
            "id": 760,
            "cosmic_signature_number": "10",
            "cosmic_signature_version": "2",
            "feature_type": "mutational_signature",
            "feature": "COSMIC Signature 10"
        }
    },
    "SOURCES": {
        "id": 150,
        "type": "Journal",
        "doi": "10.1056/NEJMoa1500596",
        "nct": "NCT01876511",
        "pmid": 26028255,
        "url": "https://doi.org/10.1056/NEJMoa1500596",
        "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20."
    },
    "VARIANTS": {
        "id": 760,
        "cosmic_signature_number": "10",
        "cosmic_signature_version": "2",
        "feature_type": "mutational_signature",
        "feature": "COSMIC Signature 10"
    }
}